Geographic Variations in Species Distribution and Echinocandin and Azole Antifungal Resistance Rates among Candida Bloodstream Infection Isolates: Report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009)

被引：166

作者：

Pfaller, Michael A. ^{[1
]}

Moet, Gary J. ^{[1
]}

Messer, Shawn A. ^{[1
]}

Jones, Ronald N. ^{[1
,2
]}

Castanheira, Mariana ^{[1
]}

机构：

[1] JMI Labs, N Liberty, IA 52317 USA

[2] Tufts Univ, Sch Med, Boston, MA 02111 USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2011年 / 49卷 / 01期

关键词：

INVASIVE CANDIDIASIS; CASPOFUNGIN RESISTANCE; GLABRATA; SUSCEPTIBILITY; VORICONAZOLE; MICAFUNGIN; EPIDEMIOLOGY; FLUCONAZOLE; BREAKPOINTS; SECONDARY;

D O I：

10.1128/JCM.01398-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Antifungal testing results from the SENTRY Antimicrobial Surveillance Program (2008 to 2009) were analyzed for regional variations of invasive Candida species infections. Among 2,085 cases from the Asian-Pacific (APAC) (51 cases), Latin American (LAM) (348 cases), European (EU) (750 cases), and North American (NAM) (936 cases) regions, Candida albicans predominated (48.4%), followed by C. glabrata (18.0%), C. parapsilosis (17.2%), C. tropicalis (10.5%), and C. krusei (1.9%). Resistance to echinocandins (anidulafungin [2.4%] and micafungin [1.9%]) and azoles (3.5 to 5.6%) was most prevalent among C. glabrata isolates, as determined using recently established CLSI breakpoint criteria. C. glabrata isolates were more common in NAM (23.5%), and C. albicans isolates were more common in APAC (56.9%), with C. parapsilosis (25.6%) and C. tropicalis (17.0%) being more prominent in LAM. Emerging resistance patterns among C. glabrata cases in NAM require focused surveillance.

引用

页码：396 / 399

页数：4

共 22 条

[1] Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazol [J].